1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Theraclion SA

Theraclion SA

0.59
EUR
+0.00
(+0.51%)
36.70MMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.21
0.35
0.28
0.32
0.22
0.18
0.05
0.06
0.04
0.04
0.02
0.02
- -
Basic EPS, GAAP
-1.35
-1.24
-1.48
-1
-0.82
-0.71
-0.24
-0.24
-0.16
-0.17
-0.08
-0.12
-0.09
- -
Free Cash Flow per Basic Share
-1.47
-1.51
-1.35
-1.27
-0.91
-0.57
-0.25
-0.21
-0.17
-0.19
-0.06
-0.04
-0.12
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.25
0.69
0.16
0.85
0.46
-0.06
-0.01
-0.2
-0.05
0.02
0.12
- -
-0.04
-0.04
Tangible Book Value per Share
-1.56
0.47
-0.12
0.67
0.31
-0.18
-0.07
-0.25
-0.1
-0.03
0.09
-0.02
-0.06
-0.06
Basic Weighted Avg Shares
3
4
4
7
8
9
16
16
23
30
47
47
61
53
Sales/Revenue/Turnover
- -
1
2
2
2
2
3
1
1
1
2
1
1
- -
Operating Margin (%)
-31,355.88
-620.13
-472.98
-402.43
-291.99
-361.75
-168.66
-569.27
-356.55
-507.74
-172.23
-831.45
-537.86
- -
Depreciation Expense
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
3
1
1
- -
Net Income, GAAP
-4
-5
-6
-7
-6
-6
-4
-4
-4
-5
-4
-6
-6
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-28,350.41
-579.48
-418.88
-351.31
-256.04
-318.56
-136.24
-524.9
-253.92
-401.83
-201.68
-693.61
-479.76
- -
Working Capital
1
5
4
9
7
2
3
4
4
5
12
5
7
7
LT Debt
6
4
- -
- -
- -
- -
- -
4
3
3
2
1
4
4
Total Equity
-4
3
1
6
3
-1
- -
-3
-1
1
6
- -
-3
-3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-363.26
-206.21
-137.52
- -
- -
- -
- -
- -
-118.7
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
1
LT Borrowings
1
- -
4
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
61
Market Capitalization
16
15
37

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
8
- -
11
Cash, Cash Equivalents & STI
4
- -
3
Accounts Receivable, Net
- -
- -
- -
Inventories
2
- -
3
Total Current Liabilities
4
- -
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
2,270,574.56%
Free Cash Flow
19.35%
45.73%
247.52%
Net Income, GAAP
1.84%
11.57%
-1.16%
Sales/Revenue/Turnover
12.1%
23.68%
42.89%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2
2024
- -
- -
1
2025
- -
- -
1

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.08
2024
- -
- -
-0.12
2025
- -
- -
-0.09

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Martin Deterre
Full Time Employees
36
Sector
Health technology
Industry
Medical specialties
Address
102 Rue Etienne Dolet Malakoff IF France 92240
IPO Date
Apr 25, 2014
Website
theraclion.fr
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Theraclion SA (ALTHE.PA), a French MedTech company founded in 2004 and headquartered in Malakoff near Paris, develops, manufactures and markets robotic high-intensity focused ultrasound (HIFU) platforms for non-invasive echotherapy treatments as alternatives to surgery. The company offers SONOVEIN, a CE-marked robotic system for treating varicose veins without incisions, scars or sedation, including the upgraded SONOVEIN HD version with advanced imaging from SuperSonic Imagine; ECHOPULSE, a non-invasive device for outpatient treatment of thyroid nodules and breast fibroadenomas, preserving organ function and tissue integrity; and related consumables such as EPack for skin protection and image optimization. Theraclion operates in Europe, the Middle East, China and the United States (investigational use only), targeting vascular, endocrine and oncology segments with a recurring revenue model from installed bases and machine sales to clinics and physicians. In February 2025, the company secured a €3 million convertible bond financing commitment from historical shareholders Furui and Unigestion, with potential expansion to €6 million, extending its cash runway to Q4 2025 to support R&D in AI, acoustics and 3D robotics like SpeedPulse technology, US FDA pivotal study completion, Chinese market access and revenue goals of €2.5 million in 2025 and €5 million in 2026; first-half 2025 revenue rose 89% to €834,000. A spin-off from Inserm and EDAP Techomed, Theraclion employs around 30 people focused on technological and clinical advancements, with SONOVEIN now in over 15 countries and more than 3,500 procedures performed globally.